Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
1.730
-0.040 (-2.26%)
Sep 3, 2025, 4:00 PM - Market closed
Mereo BioPharma Group Revenue
Mereo BioPharma Group had revenue of $500.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $500.00K, down -50.00% year-over-year.
Revenue (ttm)
$500.00K
Revenue Growth
-50.00%
P/S Ratio
550.48
Revenue / Employee
$13,889
Employees
36
Market Cap
275.24M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | 10.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | 49.37M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MREO News
- 16 days ago - āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2 - Business Wire
- 23 days ago - Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewsWire
- 7 weeks ago - Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI - Seeking Alpha
- 4 months ago - Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewsWire
- 5 months ago - Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights - GlobeNewsWire
- 6 months ago - Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 8 months ago - Mereo BioPharma Provides Update on Lead Clinical Programs - GlobeNewsWire
- 8 months ago - Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire